At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Pegcetacoplandrug
Likely dose
Pegcetacoplan 1080 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
In Brief
A Phase 2 clinical trial evaluating Pegcetacoplan for Transplant-Associated Thrombotic Microangiopathy. Completed, enrolled 12 participants across 14 sites in 5 countries.
Detailed Summary
The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Greece, Italy, Spain, United States
CollaboratorsApellis Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartFeb 2022
Primary CompletionDec 2024
TodayJul 2026
First PostedDec 8, 2021
Enrollment StartFeb 1, 2022
Primary CompletionDec 8, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.6 years ago
Interventions
Pegcetacoplandrug
20-cc glass vials-1080 mg